/Cl --coupled biogenic amine transporters are the primary targets of therapeutic and abused drugs, ranging from antidepressants to the psychostimulants cocaine and amphetamines, and to their cognate substrates. Here we determine X-ray crystal structures of the Drosophila melanogaster dopamine transporter (dDAT) bound to its substrate dopamine, a substrate analogue 3,4-dichlorophenethylamine, the psychostimulants D-amphetamine and methamphetamine, or to cocaine and cocaine analogues. All ligands bind to the central binding site, located approximately halfway across the membrane bilayer, in close proximity to bound sodium and chloride ions. The central binding site recognizes three chemically distinct classes of ligands via conformational changes that accommodate varying sizes and shapes, thus illustrating molecular principles that distinguish substrates from inhibitors in biogenic amine transporters.
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/Cl --coupled biogenic amine transporters are the primary targets of therapeutic and abused drugs, ranging from antidepressants to the psychostimulants cocaine and amphetamines, and to their cognate substrates. Here we determine X-ray crystal structures of the Drosophila melanogaster dopamine transporter (dDAT) bound to its substrate dopamine, a substrate analogue 3,4-dichlorophenethylamine, the psychostimulants D-amphetamine and methamphetamine, or to cocaine and cocaine analogues. All ligands bind to the central binding site, located approximately halfway across the membrane bilayer, in close proximity to bound sodium and chloride ions. The central binding site recognizes three chemically distinct classes of ligands via conformational changes that accommodate varying sizes and shapes, thus illustrating molecular principles that distinguish substrates from inhibitors in biogenic amine transporters.
Signals by the biogenic amine neurotransmitters-dopamine (DA) 1 , serotonin 2 and noradrenaline 3 -at chemical synapses are terminated by the cognate neurotransmitter sodium symporters (NSSs) [4] [5] [6] [7] . Biogenic amines play profound roles in the development and function of the nervous system, as well as in animal behaviour and activity; thus NSSs are central to normal neurophysiology and are the targets of a spectrum of therapeutic and illicit agents, from antidepressants and antianxiety medications to cocaine and amphetamines 8 . Experimental and computational studies have shown that the DA, serotonin (SERT) and noradrenaline (NET) transporters harbour a conserved structural fold 9, 10 , first seen in the structure of LeuT 11 . Owing to variations in amino acid sequences 12 , however, the biogenic amine transporters possess distinct yet overlapping pharmacological 'fingerprints' 13 . The dopamine transporter (DAT) 14 removes DA from synaptic and perisynaptic spaces, thus extinguishing its action at G-protein coupled DA receptors. To drive the vectorial 'uphill' movement of extracellular DA into presynaptic cells, DAT couples substrate transport to pre-existing sodium and chloride transmembrane gradients. Congruent with the multifaceted roles of DA in the nervous system, perturbation of dopaminergic signalling by disruption of native DAT function has profound consequences [15] [16] [17] . On the one hand, the amphetamines, potent and widely abused psychostimulants, are DAT substrates that enhance synaptic levels of DA both by competing with DA transport by DAT and by inducing the release of DA from synaptic vesicles into the cytoplasm, from where DA is then effluxed through DAT into the synaptic space [18] [19] [20] [21] [22] [23] [24] . On the other hand, the Erythroxylum coca leaf-derived alkaloid, cocaine, as well as synthetic cocaine derivatives are competitive inhibitors of DAT and enhance extracellular DA concentrations by locking the transporter in a transport inactive conformation 14, [25] [26] [27] . Widely prescribed antidepressants specifically inhibit serotonin and noradrenaline uptake and typically have weaker affinities towards DAT 28, 29 . Mutagenesis, chemical modification, binding and transport studies have implicated the central or S1 binding site in DAT, akin to the leucine and tryptophan site in LeuT, as the binding site occupied by DA, amphetamines, cocaine and antidepressants 25, 26, 30 . Moreover, the X-ray structure of a transport-inactive Drosophila melanogaster DAT (dDAT) in complex with nortriptyline shows the antidepressant bound at the central site 9, 31 . Nevertheless, none of these studies have visualized the binding of DA, amphetamine or cocaine to an active DAT, nor have they illuminated distinctions in ligand pose and transporter conformation between substrates and inhibitors. Here we present X-ray structures of dDAT with substrates DA, methamphetamine or D-amphetamine, with the DA analogue 3,4-dichlorophenethylamine (DCP), and with cocaine or cocaine analogues.
Resurrection of transport activity
The previously reported structure of the dDAT-nortriptyline complex exploited a transport-inactive variant with five thermostabilizing mutations (dDAT cryst ) 9 . We recovered transport function yet retained favourable crystallization properties by reverting three thermostabilizing mutations (V275A, V311A and G538L) to their wild-type identities and by shifting the deletion of extracellular loop 2 (EL2; Extended Data Fig. 1 ). This minimal functional construct, dDAT mfc , has a melting temperature of 48 uC 32 , exhibits DA transport with a K M of 8.2 6 2.3 mM and V max of 2.4 6 0.2 pmol min 21 per 10 6 cells, compared to wild-type dDAT (dDAT wt ) with a K M of 2.1 6 0.7 mM and V max of 4.5 6 0.4 pmol min 21 per 10 6 cells (s.e.m., Fig. 1a ). The dDAT mfc construct binds nisoxetine with a K d of 36 nM compared to a K i of 5.6 nM for wild-type dDAT 31 (Extended Data Fig. 2 ). The central binding site in DAT, NET and SERT can be divided to subsites A, B and C 29, 33 . Subsites A and C are well conserved in dDAT versus human DAT (hDAT), whereas subsite B, a pocket sculpted by TMs (transmembrane helices) 3 and 8, differs from hDAT in that residues lining this pocket in dDAT are Asp121 and Ser426 (Extended Data Fig. 3 ). We introduced mutations D121G (TM3) and S426M (TM8) into the dDAT cryst and dDAT mfc constructs to mimic hDAT subsite B 33 . These mutations enhanced the affinities for nisoxetine, b-CFT (2b-carbomethoxy-3b-(4-fluorophenyl)tropane) and DCP (Extended Data Figs 2, 4) . Although constructs harbouring subsite B substitutions improved crystallization propensity, transport activity was extinguished (Extended Data Fig. 3c ). Nevertheless, structures bearing these mutations were solved in complexes with cocaine, b-CFT, RTI-55(2b-carbomethoxy-3b-(4-iodophenyl)tropane) or DCP (Supplementary Table 1 ). In the cocaine, RTI-55 and DCP complexes, superposition of structures with subsite B mutations onto structures of dDAT mfc complexes did not reveal prominent structural changes in the binding pocket or deviations in the positions of bound ligand (Extended Data Table 1 ).
Dopamine bound to central binding site
The structure of dDAT mfc bound to DA displays an outward-open conformation (Fig. 1b) where DA is situated in the central binding site, surrounded by TMs 1, 3, 6 and 8. The amine group points towards subsite A and interacts with the carboxylate of Asp46 at a distance of 3 Å . The catechol group occupies a subsite B cavity sculpted by Ala117, Val120, Asp121, Tyr124, Ser422 and Phe325 (Fig. 1c, d ), residues predicted to interact with DA using homology models of DAT based on the substrate-bound occluded state of LeuT, analysis of uptake kinetics, and cysteine labelling studies 10, 25, 26, 34 . Despite a lack of steric interference from DA, Phe319, which is equivalent to Phe253 in LeuT (in which it occludes solvent access to the LeuT binding pocket), remains splayed away from DA, in an orientation seen in the nortriptyline-bound structure 9, 11 . The location and interactions of DA with dDAT recall predictions made through homology models of hDAT, although discrepancies between the cocrystal structure and the homology models are also evident. Site-directed mutagenesis and molecular dynamics simulations pointed to the crucial role of Asp46 (Asp79 in hDAT) in the recognition of DA 10, 25, 34, 35 , a residue conserved amongst biogenic amine neurotransmitters. GAT (c-amino butyric acid transporter), GlyT (glycine transporter), and LeuT contain glycine at the equivalent position owing to the presence of a compensatory carboxylate group in the substrates 11 . One notable difference between the dDAT mfc -DA structure and previous hDAT models, however, is a rotation in the x1 torsion angle of ,130u in the side chain of Asp46 to maintain a 3 Å distance to the amine group of DA. This rotation severs the indirect coordination between Asp46 and the sodium ion at site 1 as observed in the nortriptyline-dDAT cryst complex 9 . Unlike previous simulation studies where DA binds in a dehydrated pocket 34 , we observed nonprotein electron density 3.1 Å from the amine group of DA, into which a water molecule was modelled. This water molecule forms a hydrogen bond with the water molecule that coordinates the sodium ion at site 1, resulting in a molecular network that links DA to the ionbinding sites. In the case of LeuT, substrate interaction with sodium site 1 is direct, with the carboxylate of leucine coordinating the sodium ion 11 . The catechol ring of DA interacts with TMs 3 and 8 by hydrogen bonds with the carboxylate group of Asp121 (Fig. 1d) . Modelling studies predicted that DA occupies multiple poses within the binding pocket with the meta-hydroxyl either interacting with residues in TM8 equivalent to Ser421 or to Ser422 (dDAT numbering) 34 . By contrast, in the structure of dDAT mfc -DA, the para-hydroxyl group interacts with both the carbonyl oxygen of Ala117 and the carboxylate of Asp121 at distances of 2.8 and 3.1 Å , respectively, whereas the meta-hydroxyl group interacts with the side chain of Asp121 at a distance of 2.7 Å and faces Ser422 in TM8 at a distance of 3.8 Å .
The residues poised to interact with the catechol ring vary across DAT orthologues with invertebrate DAT orthologues retaining alanine and aspartate at positions equivalent to residues 117 and 121, respectively, whereas in most mammalian DATs residue Asp121 is replaced by glycine and Ala117 by serine 9 , the latter of which could act as a surrogate hydrogen bond partner for the catechol group. With hNET, the equivalent residues at 117 and 121 are Ala and Gly, raising the possibility of the catechol group of noradrenaline interacting with the hydroxyl of Ser420 in hNET (TM8; equivalent to Ser422 of dDAT and Ala423 in hDAT). We propose that these compensatory variations within subsite B dictate catecholamine recognition common to both DAT and NET. To explain why NET binds noradrenaline and DA with nearly equal apparent affinity yet DAT prefers DA 31 , we must invoke longer-range, indirect interactions, perhaps involving subsite B and the non-helical TM6a-6b 'linker' because the 'Phebox' surrounding the b-carbon position is conserved between NET and DAT.
Recognition of D-amphetamine and methamphetamine
To understand how amphetamines are transported by DAT despite lacking the hydroxyl groups of the catecholamines, we characterized the interactions between amphetamines and dDAT by binding assays and crystallographic studies. (1)-methamphetamine displaces [ 3 H]nisoxetine binding to dDAT mfc with a K i value of 31 mM, whereas D-amphetamine, which lacks the N-methyl group present in methamphetamine, has a K i of 86 mM (Fig. 2a) . D-amphetamine is 10 to 100-fold weaker in its ability to inhibit DA transport in the dDAT compared to its mammalian counterparts 31 . The weaker affinities of dDAT for amphetamines compared to mammalian DATs may be due in part to differences in residues of subsite B. Indeed, the presence of Asp121 and Ser426 in invertebrate DATs creates a polar environment that does not complement the non polar benzyl groups of amphetamines (Fig. 1d) . In mammalian DATs both methamphetamine (K i 5 0.5 mM) and D-amphetamine (K i 5 0.6 mM) are nearly as effective as cocaine (0.2 mM) at inhibition of DA uptake 36 . Although the maximal rate of transport (V max ) for D-amphetamine in hDAT is fivefold lower than for DA, the K M values range from 0.8 to 2 mM 22 , consistent with the notion that mammalian subsite B is more complementary towards the binding of amphetamines than subsite B in invertebrate DATs.
The structures of (1) and D-amphetamine lie closer to Asp46 at subsite A with hydrogen bonding distances of 2.9 Å , and the main chain carbonyl of Phe319 is positioned nearby at 3.3 Å (Fig. 2c) . The amine group of D-amphetamine interacts with Asp46, which does not undergo the rotameric shift as seen in the DA-bound structure because D-amphetamine is situated in the centre of the pocket and not displaced by 2.8 Å towards TMs 3 and 8 as seen with DA ( Fig. 2d ). By contrast with earlier findings 25 , we do not observe a disruption of the hydrogen bond between Asp46 and Tyr124 despite Asp46 clearly forming a hydrogen bond with the primary amine of D-amphetamine. Phe325 retains edge-to-face aromatic interactions with the phenyl group of amphetamines by way of a contraction of the TM6a-6b linker in comparison to the DA-bound state. Amphetamines adopt poses in the central binding that allow for interactions between their amino and aromatic groups and transporter subsites, thus explaining how the sterically smaller amphetamines compete with DA and act as substrates despite the absence of catechol-like hydroxyl groups.
Dopamine analogue stabilizes partially occluded state
DA is prone to oxidation and thus we sought a stable analogue for crystallographic and biochemical studies. Multiple high-affinity biogenic amine transporter inhibitors harbour halogen groups on the aromatic rings predicted to occupy subsite B 33,37 and thus we screened halogenated phenethylamine derivatives for binding to dDAT (Extended Data Fig. 4d ). We discovered that 3,4-dichlorophenethylamine (DCP) possessed the greatest affinity and, because it is approximately isosteric to DA, was selected for further study (Fig. 3a) .
One DCP molecule is lodged in the central binding pocket, with the amine group forming a hydrogen bond with Asp46, and the dichlorophenyl ring bordered by Val120 and Phe325 in subsites B and C, respectively ( Fig. 3b-d, Extended Data Fig. 6 ). The position of DCP in the pocket is closer to that of D-amphetamine in dDAT and of substrate leucine in LeuT 11 , whereas the position of DA is shifted towards TMs 3 and 8, probably owing to hydrogen bonding between the catechol hydroxyl groups and Asp121. As a result, the position of Asp46 in the DCP-bound structure is superimposable with the positions seen in the amphetamine-bound structures. Interestingly, the side chain of Phe319 rotates to occlude the binding pocket, a conformational change not seen in any of the inhibitor-or DA-bound structures (Fig. 3c, d ). This rotamer of Phe319 prevents solvent access to the pocket, leaving an aperture only ,1 Å wide on the extracellular side of DCP. The equivalent residue in LeuT, Phe253, adopts the same 
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G2015 Macmillan Publishers Limited. All rights reserved orientation in the occluded substrate-bound form, supporting the notion that the rearrangements seen in the DCP-dDAT mfc structure are on the pathway to a LeuT-like occluded state of dDAT 11 . Unlike the DA-bound state, there is no evidence of a water molecule associated with DCP in the structures, suggesting that formation of an occluded state is associated with dehydration of the binding pocket (Fig. 3c, d ), similar to LeuT.
The partially occluded binding pocket of the DCP-dDAT mfc structure primarily results from rotations of TM1b and 6a 'into' the binding pocket, towards scaffold helices 3 and 8 and around axes centred near the non helical regions of TMs 1b and 6a (Extended Data Fig. 6a,  c) . In LeuT, studies of the transporter in solution and in the crystal show that TMs 1b and 6a, along with EL4, undergo conformational changes to close the extracellular gate 11, 38, 39 . Comparisons with the outward-open nortriptyline-bound state of dDAT 9 and the occluded state of LeuT indicate that, although the DCP ligand is nearly inaccessible to the extracellular solution, the inward rotations of TMs 1b (5.6u) and 6a (,7u) are less pronounced in dDAT than in LeuT 11 (Extended Data Fig. 6f, g ). Nevertheless, these helical rotations position the side chain of Phe319 over the extracellular face of the binding pocket, and are associated with a series of phenylalanine side chain reorientations (Fig. 3e) . TM11 undergoes an outward movement of 6u to accommodate these side chain shifts, and an inward movement of 5u is observed in TM2 (Extended Data Fig. 6b, d ). Interestingly, TMs 2, 7 and 11 at the inner leaflet of the plasma membrane form a second cholesterol binding site (site 2) where a density for cholesteryl hemisuccinate (CHS) was observed in all the reported structures. Indeed, CHS enhances dDAT inhibitor affinity and we speculate that, in native membranes, cholesterol binds to sites 1 and 2, perhaps stabilizing DAT in an outward-open state (Extended Data Fig. 7) 39-41 . The occluded state is a Michaelis-Menten-like transport intermediate for LeuT and related transporters such as BetP, Mhp1 and MhsT [42] [43] [44] when bound to substrate. Disparities in conformations observed between LeuT and dDAT in the presence of substrate, however, may reflect bona fide differences that are dependent on the relative stabilities of distinct substrate-bound states. Nevertheless, we cannot exclude crystal lattice effects, Fab binding, lipid, or solutes present in the crystallization solutions that may favour the outwardopen conformation observed for the dDAT-substrate complexes reported here.
Cocaine binds in the central site
The structure of the dDAT mfc -cocaine complex exhibits an outwardopen conformation (Fig. 4a) with cocaine bound to the central pocket at a site overlapping the nortriptyline site 45 , adjacent to the Na1 and Na2 sodium ions and the chloride ion. The tertiary amino group of cocaine forms a salt bridge with Asp46 (TM1b) (Fig. 4b) . We observe that the TM6a-6b linker contracts, allowing Phe325 to form edge-toface aromatic interactions with the benzyl ring of cocaine (Fig. 4c) .
The negative electrostatic potential of subsite B in dDAT compared to mammalian DATs probably underlies the reduced affinity of dDAT for cocaine. Altering this charged pocket to mimic mammalian DATs with the mutations D121G and S426M yielded a dDAT construct with enhanced binding affinities for cocaine and b-CFT, but not for RTI-55 (Fig. 4d, Extended Data Fig. 4a, b) . We speculate that the carboxylate group of Asp121 does not form favourable interactions with the 4-fluorophenyl and 4-iodophenyl groups of b-CFT and RTI-55, respectively, perhaps accounting for some of the discrepancies in relative binding affinities between hDAT and dDAT.
Ligand docking studies using a homology model of DAT, in combination with biochemical binding assays and ligand-dependent disulphide trapping experiments, have probed the orientation of cocaine in the central binding site 25, 26, 30 . These studies predicted that the fluorophenyl moiety of b-CFT forms a hydrogen bond with the side chain equivalent to Asn125 in dDAT. Furthermore, the methyl ester of cocaine was thought to displace the side chain of Tyr124 to abrogate the hydrogen bond between Tyr124 and Asp46 as a mechanism of inhibiting transporter function. The dDAT mfc -cocaine structure contradicts the finding that cocaine disrupts the Asp46-Tyr124 interaction and does not place the side chain of Asn125 in a location where it could interact with the fluorophenyl group of b-CFT.
To validate the cocaine-bound structure and conclusively identify residues that interact with tropane-based ligands, structures of dDAT were solved in the presence of the cocaine analogues b-CFT and RTI-55. Anomalous scattering by the iodide of RTI-55 corroborated the location and placement of the aromatic moiety of cocaine proximal to TMs 3 and 8 (Extended Data Fig. 8a ). The 
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G2015 Macmillan Publishers Limited. All rights reserved were previously predicted to interact with these tropane-based inhibitors 25, 46, 47 (Fig. 4b) . A comparison with the antidepressant nortriptyline-dDAT cryst structure 9 reveals that the smaller benzoate group of cocaine is accommodated with a shift of the TM6a-6b linker and a rotation of Phe325 into the binding pocket, which was not previously predicted. The tropane rings of cocaine, b-CFT and RTI-55 are bordered by Phe43, Ala44, Asp46, Ala48, Phe319 and Ser421. The side chain of Phe319 maintains a similar orientation as seen in the dDAT-nortriptyline structure owing to the bulky tropane ring and the methyl ester group present in all three tropane inhibitors. Overall, the docking and photolabelling studies predicted the location and orientation of cocaine and its analogues to overlap with the DA-binding site of DAT 25, 26, 30 . Our structures validate these findings yet indicate distinctions that have implications for the mechanism of inhibition by tropane ligands. Taken together, structures of dDAT in complex with tropane ligands suggest that inhibition is achieved by combining a free amine with bulky tropane and aromatic moieties to limit conformational movements of the transporter.
Plasticity of the substrate binding pocket
The inhibitor-and substrate-bound structures of dDAT indicate that the binding pocket of dDAT accommodates ligands of varying sizes largely by adjusting the orientation of the discontinuous region of TM6 and the side chains of Phe319 and Phe325 ( Fig. 5 ; Extended Data Table 2a ). Ligand recognition by dDAT is bipartite and requires an amine group that interacts with the carbonyl oxygens of Phe43 and Phe319 or the carboxylate of Asp46 in subsite A, in combination with an aromatic group that is stabilized by van der Waals interactions with residues lining a hydrophobic cleft formed by TMs 3, 6, and 8 of subsite B. The substrates DA, D-amphetamine, and methamphetamine each contain one phenyl ring linked to an ethylamine chain, requiring Phe325 to rotate inward to contract the size of the pocket and maintain edge-to-face aromatic interactions with these ligands (Extended Data Fig. 8c, Fig. 5a, e) . In the DCP-dDAT mfc structure, Phe319 also rotates inward to cover the ligand, and similar to LeuT, this reorientation of Phe319 is required for the formation of the occluded state (Extended Data Fig. 8d, Fig. 5b, e) . In order for Phe319 to cover DCP in the pocket, rotation of Phe319 is accompanied by the inward tilting of TM6a to bring the hinge region of TM6 towards the ligand (Extended Data Fig. 6 ). Accommodation of the single phenyl rings in tropane inhibitors requires Phe325 to assume a position similar to that seen in the DA-bound structure to provide edge-to-face aromatic interactions (Fig. 5c, f) . To enlarge the binding pocket for multiple aromatic rings, the side chains of Phe319 and Phe325 are splayed outward as seen in the antidepressant-bound structures (Fig. 5d, f) .
These structures provide a molecular explanation for the distinction between substrates and inhibitors of biogenic amine transporters. Substrates such as DA and amphetamines contain amine and aromatic functional groups at opposing ends of the molecule that interact with both the extracellular gate of TMs 1b and 6a and the scaffold TMs 3 and 8. In contrast, inhibitors exploit the flexibility of the binding pocket to bind to the outward open transporter with high affinity, acting like wedges to lock the transporter in an outward-open conformation. Tropane ligands achieve inhibition by inserting benzyl or halo-phenyl groups into the cavity of subsite B, with the tropane ring oriented to sterically hinder the movement of the extracellular gate. Antidepressants, like nortriptyline, differ from tropane inhibitors by coupling bulky aromatic moieties with an amine group to block conformational flexibility in the transporter.
Conclusions
Structures of dDAT in complex with both substrates and inhibitors emphasize the role of subsites in the pocket of dDAT in defining ligand specificity, a concept that can be expanded to understand variation in pharmacological profiles between biogenic amine transporters 33 . The DA-bound structure suggests that interactions between the catechol ring and subsite B, together with hydrogen bonding between the amine group of DA and Asp46, drive closure of the extracellular gates TMs 1b and 6a to form the occluded state. D-amphetamine and methamphetamine are bound in a manner distinct from DA in the pocket, and the absence of hydroxyl groups in amphetamines indicates that hydrophobic interactions must be sufficient for amphetamines to interact with subsite B residues and bridge the scaffold TMs 3 and 8 with the extracellular gating helices. The conformations of the DA, amphetamine and DCP-bound complexes probably represent snapshots following substrate and ion binding but before full closure of the extracellular gate, rather than the occluded conformation seen in LeuT bound to its substrates 11, 48, 49 . Questions extending from the substrate-bound structures involve the conformational changes required for DAT to transition to other states of the transport cycle and the roles of subsites A and B in neurotransmitter transport by mammalian DATs. Furthermore, the inhibitor-bound structures of dDAT provide a scaffold for addressing the mechanistic distinction between addictive and non-reinforcing analogues of cocaine 25, 45, 50 .
Online Content Methods, along with any additional Extended Data display items, are available in the online version of the paper; references unique to these sections appear only in the online paper. 51, 52 . Membranes harvested from cells post-infection were homogenized with 13 TBS (20 mM Tris pH 8.0, 100 mM NaCl) and solubilized with a final concentration of 20 mM n-dodecyl b-D-maltoside (DDM) and 4 mM cholesteryl hemisuccinate (CHS) in 13 TBS. Detergent-solubilized material was incubated with cobalt-charged metal affinity resin and eluted with 13 TBS containing 1 mM DDM and 0.2 mM CHS along with 80 mM imidazole (pH 8.0). The GFP-His 8 tag was removed using thrombin digestion followed by concentrating the metal ion affinity purified protein. The thrombin-digested protein was subjected to size exclusion chromatography through a Superdex 200 10/300 column pre-equilibrated with buffer containing 20 mM Tris pH 8.0, 300 mM NaCl, 4 mM decyl b-D-maltoside, 0.2 mM CHS and 0.001% (w/v) 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (POPE). Peak fractions greater than 0.5 mg ml 21 were collected and pooled together. Ascorbic acid (25 mM) was added to the protein solution used to crystallize the DA-dDAT mfc complex, to serve as antioxidant. All procedures were carried out at 4 uC. Fab complexation and crystallization. Antibody fragment (Fab) 9D5 was used to complex with the protein at a molar ratio of 1.2 (Fab):1 (protein). The Fab-DAT complex solution was incubated with 1-2 mg solid drug for 30 min on ice followed by concentration in a 100 kDa cutoff concentrator to 3.5-5 mg ml 21 . The concentrated protein was spun down to remove excess drug and insoluble aggregates and plates were set up by hanging drop vapour diffusion. Crystals of Fab-DAT complex grew primarily in conditions containing PEG 400 or PEG 350 monomethyl ether or PEG 600 as the precipitant (Extended Data Table 2b ). The pH range of crystallization was 8.0-9.0 for dDAT cryst -based constructs and in the range of 6.5-8.0 with dDAT mfc -based constructs (Extended Data Table 2b ). Crystals of dDAT mfc were primarily obtained by streak seeding with a cat whisker dipped in crystals formed with sub B containing constructs, 2-5 days after drops were set up. All crystals were grown at 4 uC.
Data collection and structure refinement. Crystals were directly flash-cooled in liquid nitrogen when the PEG 400 concentration in the mother liquor exceeded 36%. For crystals grown in wells containing less than 36% PEG 400, crystals were transferred into cryoprotection solution identical to the reservoir solution but with 40% PEG 400. In conditions with 30-34% PEG 600 as the primary precipitant, 10% of ethylene glycol was added to provide additional cryoprotection. Data were collected either at ALS (5.0.2; 8.2.1) or APS (24-IDC and IDE). Anomalous data for iodine containing RTI-55 complexed with dDAT was collected at 1.6 Å as described in the crystallographic data table. Data were processed using either HKL2000 52, 53 or XDS 54 . Molecular replacement was carried out for all data sets using coordinates 4M48 with Fab 9D5 and dDAT cryst used as independent search models, using PHASER in the PHENIX software suite 55, 56 .
Iterative cycles of refinement and manual model building were carried out using PHENIX and COOT 57 , respectively, until the models converged to acceptable levels of R-factors and stereochemistry. Radiolabel binding and uptake assays. All binding assays were carried out by scintillation proximity assay (SPA) method 58 . For uptake assays HEK 293S cells were infected with baculovirus expressing dDAT mfc or dDAT wt , and sodium butyrate was added to 10 mM 8-12 h postinfection. At 24 h, infected cells were adhered to Cytostar-T plates for 2 h, after which the culture media were replaced with uptake buffer (20 mM HEPES pH 7.4, 120 mM NaCl, 5 mM KCl, 2.5 mM CaCl 2 , 1.2 mM MgSO 4 , 10 mM D-glucose, 1 mM tropolone, 1 mM L-ascorbic acid 59, 60 . Uptake assays were carried out using [ 14 C]DA over a range of 0.3-60 mM in 100 ml total volume. Samples were read every five minutes for a time course over twenty-five minutes. The linear initial rate of uptake was plotted in the presence and absence of 10 mM nortriptyline to calculate the specific uptake rate. Data were fitted to a standard MichaelisMenten equation to obtain K M and V max values. The significance of specific uptake was assessed at each concentration of DA using a two-tailed Welch's t-test with 2 degrees of freedom. . One representative plot of total and background counts (in the presence of 10 mM nortriptyline) is shown of two experimental trials as squares and triangles, respectively. Data points and error bars show the average and standard deviation, respectively, of technical replicates (n 5 3). Welch's t-test indicates that the specific uptake signal at each concentration of dopamine is significant with a two-tailed P value , 0.02. e, Eadie-Hofstee plot of specific dopamine uptake shown in Fig. 1a and panels c and d of this figure. Data for dDAT wt and dDAT mfc are shown as squares and triangles, respectively, and error bars denote s.d. of technical replicates (n 5 3). f, The thermal melting curve of dDAT mfc solubilized from HEK293S membranes in the presence of 100 nM [ ARTICLE RESEARCH
